News

Genervon Biopharmaceuticals has recently announced that one if its lead products, GM604, was able to regulate the levels of a protein called TDP-43 and slow disease progression in amyotrophic lateral sclerosis (ALS) patients. ALS results in the progressive loss of structure and function of neurons, ultimately leading to their death. Symptoms depend…

Neuraltus Pharmaceuticals, Inc. recently announced it has partnered with the Clinigen Group plc’s Idis Managed Access (MA) division to launch a program for the former’s product candidate for amyotrophic lateral sclerosis (ALS), NP001. This agreement effectively makes the program available in several European territories, with an estimated growth to more countries as 2016…

Researchers from the University of Milan (UM), Italy, have recently released findings from their scientific literature review, in an effort to uncover the causes of cellular pathologies that are the hallmark of Amyotrophic Lateral Sclerosis (ALS). The findings entitled, “SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis“, published…

In a recent report published in the PLOS One journal entitled “Transforming Growth Factor Beta (TGF-β) Is a Muscle Biomarker of Disease Progression in ALS and…

The ALS Association, the country’s premier organization committed to find a cure for ALS and improving the lives of those affected by this rare disease, has just announced the viral and recently relaunched ALS Ice Bucket Challenge has played an integral role in pushing the creation of a new drug development…

Three prominent health institutions have recently come together to form the country’s largest coordinated and comprehensive initiative against amyotrophic lateral sclerosis (ALS). Last week, Johns Hopkins University’s Robert Packard Center for ALS Research, Cedars-Sinai Medical Center’s Regenerative Medicine Institute and the Massachusetts General Hospital Neurological Clinical Research Institute officially launched a joint…

Dr. Christopher Donnelly, PhD, is the first recruit for the University of Pittsburgh Brain Institute’s new Live Like Lou Center for ALS Research. A neurobiologist who co-led a study investigating hexanucleotide repeat expansion (HRE) which scientists say is the most common cause of Amyotrophic Lateral Sclerosis (ALS) and…

Johns Hopkins University researchers have announced that they will present the latest results of a study that reveals increased levels of endothelin 1 (ET-1) in astrocytes in the brain, along with increased levels of ET-B binding protein (the protein that binds to the ET-1 receptor) are associated with amyotrophic lateral sclerosis (ALS) or Lou…

The launch of Answer ALS, the largest comprehensive research project to cure Amyotrophic Lateral Sclerosis (ALS) was announced in a press release by the Johns Hopkins University’s Robert Packard Center for ALS Research in Baltimore, MD, the Cedars-Sinai…

MediciNova, a biopharmaceutical company that creates and studies small molecule medications for the management of medical conditions with unmet medical needs, is currently undergoing research on ALS patients who use non-invasive ventilation and will be treated with MN-166, also called Ibudilast, as part of a study on the management of ALS. Currently there…